Novasep-PharmaZell Invests €7.3M to Increase API Production Capacity
The Novasep-PharmaZell Group has announced a €7.3M (approximately $7.45 USD) investment for its Mourenx, France site as part of a larger project supported by...
Indian Pharma Business May Increase 8-11%, Predicts Alkem
When the epidemic subsides, Alkem Laboratories predicts that inflationary pressures and shifting regulatory standards will be the primary concerns to keep an eye on,...
Lonza To Construct $518mn Fill-Finish Plant In Switzerland
Lonza, a major CDMO, is to invest $518 million in a new, massive fill-finish manufacturing facility in Stein, Switzerland. According to the firm, the...
Pfizer And Touchlight Enter Into A Patent Collaboration
Pfizer and another pharmaceutical major, Touchlight, have come to a deal on a significant non-exclusive patent licence. Touchlight is a firm that focuses on...
AstraZeneca, GSK Weathered Q2 Storm, But Roche Stock Plunged
The standard response to any poor performance is to blame the supply chain, which has almost attained the status of a joke. However, it...
Deloitte Believes Mature R&D Firms Reap Enterprise Value
According to the third Real-World Evidence (RWE) benchmarking survey published in June 2022 by Deloitte, there is a segmentation of outcomes between businesses with...
Sanofi Sets Up Fund To Enable Firms In Low-Income Countries
The Paris-based pharmaceutical company is setting up a fund to assist companies who want to provide healthcare solutions in neglected areas. The objective is...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...